Modulation of endotoxin- and enterotoxin-induced cytokine release by in vivo treatment with β-(1,6)-branched β-(1,3)-glucan

Infection and Immunity

Volumn 67, Issue 1, 1999, Pages 244-252

  Soltys, Jindrich ^a   Quinn, Mark T ^a  

^a MONTANA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 1,3 GLUCAN; CYTOKINE; ENDOTOXIN; ENTEROTOXIN; ESCHERICHIA COLI LIPOPOLYSACCHARIDE; GAMMA INTERFERON; IMMUNOMODULATING AGENT; INTERLEUKIN 2; INTERLEUKIN 6; STAPHYLOCOCCUS ENTEROTOXIN B; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; FEMALE; IMMUNOMODULATION; IN VITRO STUDY; IN VIVO STUDY; INTRAMUSCULAR DRUG ADMINISTRATION; LEUKOCYTE ACTIVATION; LYMPHOCYTE ACTIVATION; MONOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SEPSIS; TOXIC SHOCK SYNDROME;

EID: 0032919556     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/iai.67.1.244-252.1999     Document Type: Article

References (81)

1. Abel, G., and J. K. Czop. 1992. Stimulation of human monocyte beta-glucan receptors by glucan particles induces production of TNF-alpha and IL-1 beta. Int. J. Immunopharmacol. 14:1363-1373.
2. Abrams, J. S. 1997. Immunoenzymetric assay of mouse and human cytokines using NIP-labeled anti-cytokine antibodies, p. 6.20.1-6.20.11. In J. E. Coligan, A. M. Kruisbeek, D. H. Margulies, E. M. Shevach, and W. Strober (ed.), Current protocols in immunology. John Wiley & Sons, Inc., New York, N.Y.
3. Adams, D. S., S. C. Pero, J. B. Petro, R. Nathans, W. M. Mackin, and E. Wakshull. 1997. PGG-glucan activates NF-κB-like and NF-IL-6-like transcription factor complexes in a murine monocytic cell line. J. Leukocyte Biol. 62:865-873.
4. Aviles, A., R. Guzman, E. L. Garcia, A. Talavera, and J. C. Diaz-Maqueo. 1996. Results of a randomized trial of granulocyte colony-stimulating factor in patients with infection and severe granulocytopenia. Anticancer Drugs 7:392-397.
5. Babineau, T. J., A. Hackford, A. Kenler, B. Bistrian, R. A. Forse, P. G. Fairchild, S. Heard, M. Keroack, P. Caushaj, and P. Benotti. 1944. A phase 11 multicenter, double-blind, randomized, placebo-controlled study of three dosages of an immunomodulator (PGG-glucan) in high-risk surgical patients. Arch. Surg. 129:1204-1210.
6. Babineau, T. J., P. Marcello, W. Swails, A. Kenler, B. Bistrian, and R. A. Forse. 1994. Randomized phase I/II trial of a macrophage-specific immunomodulator (PGG-glucan) in high-risk surgical patients. Ann. Surg. 220:601-609.
7. Ballow, M., and R. Nelson. 1997. Immunopharmacology: immunomodulation and immunotherapy. JAMA 278:2008-2017.
8. Barnes, P. J., and I. Adcock. 1993. Anti-inflammatory actions of steroids: molecular mechanisms. Trends Pharmacol. Sci. 14:436-441.
9. Barton, B. E., and J. V. Jackson. 1993. Protective role of interleukin 6 in the lipopolysaccharide-galactosamine septic shock model. Infect. Immun. 61: 1496-1499.
10. Beutler, B., and C. van Huffel. 1994. Unraveling function in the TNF ligand and receptor families. Science 264:667-668.
11. Bleicher, P., and W. Mackin. 1995. Betafectin PGG-glucan: a novel carbohydrate immunomodulator with anti-infective properties. Annu. Rev. Pharmacol. Toxicol. 37:143-166.
12. Chihara, G. 1992. Recent progress in immunopharmacology and therapeutic effects of polysaccharides. Dev. Biol. Stand. 77:191-197.
13. Cisneros, R. L., F. C. Gibson, and A. O. Tzianabos. 1996. Passive transfer of poly-(1-6)-beta-glucotriosyl-(1-3)-beta-glucopyranose glucan protection against lethal infection in an animal model of intra-abdominal sepsis. Infect. Immun. 64:2201-2205.
14. Colotta, F., F. Re, N. Polentarutti, S. Sozzani, and A. Mantovani. 1992. Modulation of granulocyte survival and programmed cell death by cytokines and bacterial products. Blood 80:2012-2020.
15. Czop, J. K., and K. F. Austen. 1985. Generation of leukotrienes by human monocytes upon stimulation of their beta-glucan receptor during phagocytosis. Proc. Natl. Acad. Sci. USA 82:2751-2755.
16. Czop, J. K., A. V. Puglisi, D. Z. Miorandi, and K. F. Austen. 1988. Perturbation of beta-glucan receptors on human neutrophils initiates phagocytosis and leukotriene B4 production. J. Immunol. 141:3170-3176.
17. Danner, R. L., R. J. Elin, J. M. Hosseini, R. A. Wesley, J. M. Reilly, and J. E. Parillo. 1991. Endotoxemia in human septic shock. Chest 99:169-175.
18. Davis, A. R., P. L. Mascolo, P. L. Bunger, K. M. Sipes, and M. T. Quinn. 1998. Cloning and sequencing of the bovine flavocytochrome b subunit proteins, gp91-phox and p22-phox: comparison with other known flavocytochrome b sequences. J. Leukoc. Biol. 64:114-123.
19. Doita, M., L. T. Rasmussen, R. Seljelid, and P. E. Lipsky. 1991. Effect of soluble animated beta-1,3-D-polyglucose on human monocytes: stimulation of cytokine and prostaglandin E2 production but not antigen-presenting function. J. Leukoc. Biol. 49:342-351.
20. Eigler, A., B. Sinha, G. Hartmann, and S. Endres. 1997. Taming INF: strategies to restrain this proinflammatory cytokine. Immunol. Today 18: 487-492.
21. Falk, L. A. 1997. Isolation of bone marrow derived macrophages, p. 14.1.1-14.1.9. In J. E. Coligan, A. M. Kruisbeek, D. H. Margulies, E. M. Shevach, and W. Strober (ed.). Current protocols in immunology. John Wiley & Sons, Inc., New York, N.Y.
22. Farrar, M. A., and R. D. Schreiber. 1993. The molecular cell biology of interferon-gamma and its receptor. Annu. Rev. Immunol. 11:571-611.
23. Fisher, C. J. J. J., J. M. Agosti, S. M. Opal, S. F. Lowry, R. A. Balk, J. C. Sadoff, E. Abraham, R. M. H. Schein, and E. Benjamin. 1996. Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. N. Engl. J. Med. 334:1697-1702.
24. Fong, Y., L. L. Moldawer, M. Marano, H. Wei, S. B. Tatter, R. H. Clarick, U. Santhanam, D. Sherris, L. T. May, and P. B. Sehgal. 1989. Endotoxemia elicits increased circulating beta 2-IFN/IL-6 in man. J. Immunol. 142:2321-2324.
25. Fong, Y., K. J. Tracey, L. L. Moldawer, D. G. Hesse, K. B. Manogue, J. S. Kenney, A. T. Lee, G. C. Kuo, A. C. Allison, and S. F. Lowry. 1989. Antibodies to cachectin/tumor necrosis factor reduce interleukin 1 beta and interleukin 6 appearance during lethal bacteremia. J. Exp. Med. 170:1627-1633.
26. Fukumoto, T., N. Torigoe, S. Kawabata, M. Murakami, T. Uede, T. Nishi, Y. Ito, and K. Sugimura. 1998. Peptide mimics of the CTLA4-binding domain stimulate T-cell proliferation. Nat. Biotechnol. 16:267-270.
27. Gallin, E. K., S. W. Green, and M. L. Patchen. 1992. Comparative effects of particulate and soluble glucan on macrophages of C3H/HeN and C3H/HeJ mice. Int. J. Immunopharmacol. 14:173-183.
28. Gavrieli, Y., Y. Sherman, and S. A. Ben-Sasson. 1992. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J. Cell Biol. 119:493-501.
29. Gold, H. S., and R. C. Moellering, Jr. 1996. Antimicrobial-drug resistance. N. Engl. J. Med. 335:1445-1453.
30. Gorczyca, W., J. Gong, and Z. Darzynkiewicz. 1993. Detection of DNA strand breaks in individual apoptotic cells by the in situ terminal deoxynucleotidyl transferase and nick translation assays. Cancer Res. 53:1945-1951.
31. Goren, M. B. 1982. Immunoreactive substances of mycobacteria. Am. Rev. Respir. Dis. 125:50-69.
32. Haslett, C., J. S. Savill, M. K. B. Whyte, M. Stern, I. Dransfield, and L. C. Meagher. 1994. Granulocyte apoptosis and the control of inflammation. Philos. Trans. R. Soc. London Ser. B 545:327-333.
33. Hedderwick, S., and C. A. Kauffman. 1997. Opportunistic fungal infections: superficial and systemic candidiasis. Geriatrics 52:50-59.
34. Horn, D. L., S. M. Opal, and E. Lomastro. 1996. Antibiotics, cytokines, and endotoxin: a complex and evolving relationship in gram-negative sepsis. Scand. J. Infect. Dis. Suppl. 101:9-13.
35. Isoniemi, H. 1997. New trends in maintenance immunosuppression. Ann. Chir. Gynaecol. 84:164-170.
36. Jimenez, M. F., R. W. Watson, J. Parodo, D. Evans, D. Foster, M. Steinberg, O. D. Rotstein, and J. C. Marshall. 1997. Dysregulated expression of neutrophil apoptosis in the systemic inflammatory response syndrome. Arch. Surg. 132:1263-1269.
37. Kaneko, Y., and G. Chihara. 1992. Potentiation of host resistance against microbial infections by lentinan and its related polysaccharides. Adv. Exp. Med. Biol. 319:201-215.
38. Kauffman, C. A., and S. Hedderwick. 1997. Opportunistic fungal infections: filamentous fungi and cryptococcosis. Geriatrics 52:40-49.
39. Kernodle, D. S., H. Gates, and A. B. Kaiser. 1998. Prophylactic anti-infective activity of poly-[1-6]-beta-D-glucopyranosyl-[1-3]-beta-D-glucopryanose glucan in a guinea pig model of staphylococcal wound infection. Antimicrob. Agents Chemother. 42:545-549.
40. Liang, J., D. Melican, L. Cafro, G. Palace, L. Fisette, R. Armstrong, and M. L. Patchen. Enhanced clearance of a multiple antibiotic resistant Staphylococcus aureus in rats treated with PGG-Glucan is associated with increased leukocyte counts and increased neutrophil oxidative burst activity. Int. J. Pharmacol., in press.
41. Lynn, W. A. 1998. Anti-endotoxin therapeutic options for the treatment of sepsis. J. Antimicrob Chemother. 41(Suppl. A):71-80.
42. Mackin, W., D. Brunke-Reese, C. Crotty, L. Cafro, M. Daunais, L. Fisette, and P. Bleicher. 1995. Betafectin PGG-Glucan potentiates the microbicidal activities of human leukocytes measured ex vivo in healthy human volunteers. FASEB J. 9:A521. (Abstract.)
43. Mangan, D. F., and S. M. Wahl. 1991. Differential regulation of human monocyte programmed cell death (apoptosis) by chemotactic factors and pro-inflammatory cytokines. J. Immunol. 147:3408-3412.
44. Mayeux, P. R. 1997. Pathobiology of lipopolysaccharide. J. Toxicol. Environ. Health 51:415-435.
45. Meropol, N. J., N. J. Petrelli, B. J. Lipman, M. Rodriguez-Bigas, W. Hicks, H. O. J. Douglass, J. L. Smith, M. Rasey, L. E. Blumenson, L. Vaickus, F. A. Hayes, and J. M. Agosti. 1996. Granulocyte-macrophage colony-stimulating factor as infection prophylaxis in high-risk oncologic surgery. Am. J. Surg. 172:299-302.
46. Miethke, T., C. Wahl, H. Gaus, K. Heeg, and H. Wagner. 1994. Exogenous superantigens acutely trigger distinct levels of peripheral T cell tolerance/ immunosuppression: dose-response relationship. Eur. J. Immunol. 24:1893-1902.
47. Miethke, T., C. Wahl, D. Regele, H. Gaus, K. Heeg, and H. Wagner. 1993. Superantigen mediated shock: a cytokine release syndrome. Immunobiology 189:270-284.
48. Murray, H. W. 1996. Current and future clinical applications of interferon-gamma in host antimicrobial defense. Intensive Care Med. 22(Suppl. 4): S456-S461.
49. Nemunaitis, J. 1997. A comparative review of colony-stimulating factors. Drugs 54:709-729.
50. Neu, H. C. 1992. The crisis in antibiotic resistance. Science 257:1064-1072.
51. Onderdonk, A. B., R. L. Cisneros, P. Hinkson, and G. Ostroff. 1992. Anti-infective effect of poly-beta-1-6-glucotriosyl-beta-1-3-glucopyranose glucan in vivo. Infect. Immun. 60:1642-1647.
52. Opal, S. M., A. S. Cross, J. W. Jhung, L. D. Young, J. E. Palardy, N. A. Parejo, and C. Donsky. 1996. Potential hazards of combination immunotherapy in the treatment of experimental septic shock. J. Infect. Dis. 173:1415-1421.
53. Pearl, R. G. 1998. Treatment of shock - 1998. Anesth. Analg. 1998(Suppl.): 75-84.
54. Pennington, J. E. 1993. Therapy with antibody to tumor necrosis factor in sepsis. Clin. Infect. Dis. 17(Suppl. 2):S515-S519.
55. Poutsiaka, D. D., M. Mengozzi, E. Vannier, B. Sinha, and C. A. Dinarello. 1993. Cross-linking of the bela-glucan receptor on human monocytes results in interleukin-1 receptor antagonist hut not interleukin-1 production. Blood 82:3695-3700.
56. Pretus, H. A., I. W. Browder, P. Lucore, R. B. McNamee, E. L. Jones, and D. L. Williams. 1989. Macrophage activation decreases macrophage prostaglandin E2 release in experimental trauma. J. Trauma 29:1152-1156.
57. Rasmussen, L. T., and R. Seljelid. 1991. Novel immunomodulators with pronounced in vivo effects caused by stimulation of cytokine release. J. Cell. Biochem. 46:60-68.
58. Ren, Y., and J. Savill. 1995. Proinflammatory cytokines potentiate thrombospondin-mediated phagocytosis of neutrophils undergoing apoptosis. J. Immunol. 154:2366-2374.
59. Reynolds, J. A., M. D. Kastello, D. G. Harrington, C. L. Crabbs, C. J. Peters, J. V. Jemski, G. H. Scott, and N. R. Di Luzio. 1980. Glucan-induced enhancement of host resistance to selected infectious diseases. Infect. Immun. 39:51-57.
60. Roilides, E. 1994. Host defense abnormalities as causes of increased susceptibility to infections in children with HIV infection. Int. J. Med. Microbiol. Virol. Parasitol. Infect. Dis. 280:433-438.
61. Sakurai, T., T. Kaise, T. Yadomae, and C. Matsubara. 1997. Different role of serum components and cytokines on alveolar macrophage activation by soluble fungal (1→3)-beta-D-glucan. Eur. J. Pharmacol. 334:255-263.
62. Sakurai, T., I. Suzuki, A. Kinoshita, S. Oikawa, A. Masuda, M. Ohsawa, and T. Yadomae. 1991. Effect of intraperitoneally administered beta-1,3-glucan. SSG, obtained from Sclerotinia sclerotiorum IFO 9395 on the functions of murine alveolar macrophages. Chem. Pharm. Bull. (Tokyo) 39:214-217.
63. Saravolatz, L. D., J. C. Wherry, C. Spooner, N. Markowitz, R. Allred, D. Remick, M. Fournel, and J. E. Pennington. 1994. Clinical safety, tolerability, and pharmacokinetics of murine monoclonal antibody to human tumor necrosis factor-alpha. J. Infect. Dis. 169:214-217.
64. Savill, J. 1997. Apoptosis in resolution of inflammation. J. Leukoc. Biol. 61:375-380.
65. Savill, J., and C. Haslett. 1995. Granulocyte clearance by apoptosis in the resolution of inflammation. Semin. Cell Biol. 6:385-393.
66. Seljelid, R. 1986. A water-soluble aminated β-1,3-D-glucan derivative causes regression of solid tumors in mice. Biosci. Rep. 6:845-851.
67. Seljelid, R., J. Bogwald, J. Hoffman, and O. Larm. 1984. A soluble beta-1,3-D-glucan derivative potentiates the cytostatic and cytolytic capacity of mouse peritoneal macrophages in vitro. Immunopharmacology 7:69-73.
68. Seljelid, R., Y. Figenschau, J. Bogwald, L. T. Rasmussen, and R. Austgulen. 1989. Evidence that tumor necrosis induced by aminated beta 1-3D-polyglucose is mediated by a concerted action of local and systemic cytokines. Scand. J. Immunol. 30:687-694.
69. Service, R. E. 1995. Antibiotics that resist resistance. Science 270:724-727.
70. Squier, M. K. T., A. J. Sehnert, and J. J. Cohen. 1995. Apoptosis in leukocytes. J. Leukoc. Biol. 57:2-10.
71. Stevens, D. L. 1996. The toxic shock syndromes. Infect. Dis. Clin. North Am. 10:727-746.
72. Stevens, D. L. 1997. Superantigens: their role in infectious diseases. Immunol. Invest. 26:275-281.
73. Sveinbjornsson, B., C. Rushfeldt, R. Seljelid, and B. Smedsrod. 1998. Inhibition of establishment and growth of mouse liver metastases after treatment with interferon gamma and β-1,3-D-glucan. Hepatology 27:1241-1248.
74. Takeda, Y., H. Watanabe, S. Yonehara, T. Yamashita, S. Saito, and F. Sendo. 1993. Rapid acceleration of neutrophil apoptosis by tumor necrosis factor-alpha. Int. Immunol. 5:691-694.
75. Tobias, P. S., J. Gegner, R. Tapping, S. Orr, J. Mathison, J. D. Lee, V. Kravchenko, J. Han, and R. J. Ulevitch. 1997. Lipopolysaccharide dependent cellular activation. J. Periodontal Res. 32:99-103.
76. Tzianabos, A. O., and R. L. Cisneros. 1996. Prophylaxis with the immunomodulator PGG glucan enhances antibiotic efficacy in rats infected with antibiotic-resistant bacteria. Ann. N. Y. Acad. Sci. 797:285-287.
77. Wakshull, E., D. Brunke-Retse, J. Lindermuth, L. Fisette, R. S. Nathans, J. J. Crowley, J. C. Tufts, J. Zimmerman, W. Mackin, and D. S. Adams. PGG-glucan, a soluble β-glucan, enhances the oxidative burst response, microbicidal activity, and activates an NF-κB-like factor in human PMN: evidence for a glycosphingolipid b-(1,3)-glucan receptor. Immunopharmacology, in press.
78. Wakshull, E., J. Lindermuth, and J. Zimmerman. 1996. Characterization of PGG-Glucan binding to a β-glucan receptor on human leukocytes. FASEB J. 10:A1338. (Abstract.)
79. Washburn, W. K., I. Otsu, R. Gottschalk, and A. P. Monaco. 1996. PGG-glucan, a leukocyte-specific immunostimulant, does not potentiate GVHD or allograft rejection. J. Surg. Res. 62:179-183.
80. Williams, D. L., A. Mueller, and W. Browder. 1998. Glucan-based macrophage stimulators: a review of their anti-infective potential. Clin. Immunother. 5:392-399.
81. Wollenberg, G. K., L. E. DeForge, G. Bolgos, and D. G. Remick. 1993. Differential expression of tumor necrosis factor and interleukin-6 by peritoneal macrophages in vivo and in culture. Am. J. Pathol. 143:1121-1130.